Technical Analysis for SVRA - Savara, Inc.

Grade Last Price % Change Price Change
grade F 2.12 3.92% 0.08
SVRA closed up 3.92 percent on Friday, August 7, 2020, on 56 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical SVRA trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Stochastic Sell Signal Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.92%
Bollinger Band Squeeze Range Contraction 3.92%
Weak + Overbought Other 3.92%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.
Medicine Pharmaceutical Cystic Fibrosis Heart Failure Heart Diseases Treatment Of Heart Failure Staphylococcus Aureus Total Synthesis

Is SVRA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.48
52 Week Low 0.69
Average Volume 344,514
200-Day Moving Average 2.20
50-Day Moving Average 2.32
20-Day Moving Average 2.02
10-Day Moving Average 2.03
Average True Range 0.14
ADX 13.93
+DI 22.73
-DI 15.49
Chandelier Exit (Long, 3 ATRs ) 1.83
Chandelier Exit (Short, 3 ATRs ) 2.23
Upper Bollinger Band 2.17
Lower Bollinger Band 1.87
Percent B (%b) 0.83
BandWidth 14.91
MACD Line -0.06
MACD Signal Line -0.09
MACD Histogram 0.0344
Fundamentals Value
Market Cap 51.31 Million
Num Shares 24.2 Million
EPS -3.50
Price-to-Earnings (P/E) Ratio -0.61
Price-to-Sales 526.42
Price-to-Book 2.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.44
Resistance 3 (R3) 2.45 2.35 2.38
Resistance 2 (R2) 2.35 2.27 2.35 2.37
Resistance 1 (R1) 2.24 2.22 2.30 2.23 2.35
Pivot Point 2.14 2.14 2.17 2.14 2.14
Support 1 (S1) 2.03 2.06 2.08 2.01 1.89
Support 2 (S2) 1.93 2.01 1.93 1.87
Support 3 (S3) 1.82 1.93 1.86
Support 4 (S4) 1.80